BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...cancer-promoting chemokines. TARGET/MARKER/PATHWAY: Kruppel-like factor 7 (KLF7); discs large MAGUK scaffold protein 3 (DLG3; SAP102); syntaxin...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...addition, senrebotase (AGN-214868), a Phase II compound that Ipsen gained in its 2013 acquisition of Syntaxin Ltd....
...even which cell types they target. Ipsen added the recombinant capabilities through a partnership with Syntaxin Ltd....
...AGN-214868 ; SXN100323), a targeted secretion inhibitor that has completed a Phase II trial, which Syntaxin...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...expression of the miR-183 complex could help treat pain. Karolinska Institute Translation in Brief Stroke Syntaxin...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Neurology

...the scrambled peptide. Next steps could include testing the compound in other stroke models. TARGET/MARKER/PATHWAY: Syntaxin...
...Neurodegenerative Diseases, Pittsburgh, Pa. email: redox@pitt.edu Julian Zhu University of Pittsburgh HIV tat protein (HIV tat) Potassium channel Kv2.1 (KCNB1) Syntaxin...
BioCentury | Mar 31, 2014
Finance

LSP's steady hand

...Inc. with a lead HCV vaccine program in Phase II development. Another recent exit was Syntaxin Ltd....
...in the company's £16 million ($32.8 million) series B round in 2007. At the time, Syntaxin's...
...a recombinant therapeutic protein that was in preclinical development to treat respiratory diseases. Last year, Syntaxin...
BioCentury | Feb 3, 2014
Company News

NightstaRx management update

...London, U.K. Business: Gene/Cell therapy, Ophthalmic Hired: Melanie Lee as CEO, formerly CEO of Syntaxin Ltd....
BioCentury | Jan 30, 2014
Financial News

NightstaRx debuts with L12 million from Syncona

...choroideremia, an inherited form of progressive blindness. NightstaRx's CEO is Melanie Lee, formerly CEO of Syntaxin Ltd....
BioCentury | Jul 22, 2013
Finance

Highlights of weekly biotech stock moves

...Euronext:IPN; Pink:IPSEY) edged down €0.11 to €30.01 last week after acquiring the 90% of partner Syntaxin Ltd....
...million) in cash up front, plus about €130 million ($169.8 million) in milestones. Ipsen gains Syntaxin's...
BioCentury | Jul 22, 2013
Company News

Ipsen, Syntaxin, Harvard deal

...Ipsen acquired the 90% of partner Syntaxin it did not already own for €28 million ($36.6...
...Bristows LLP advised Ipsen, and Rothschild and Allen & Overy LLP advised Syntaxin. Ipsen and Syntaxin...
...Ipsen and Syntaxin partnered in 2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's...
BioCentury | Jul 16, 2013
Company News

Ipsen acquires Syntaxin

...Ipsen Group (Euronext:IPN; Pink:IPSEY) acquired the 90% of partner Syntaxin Ltd. (Abingdon, U.K.) it did not already...
...in cash up front, plus about EUR 130 million ($169.8 million) in milestones. Ipsen gains Syntaxin's...
...Ipsen and Syntaxin partnered in 2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's...
Items per page:
1 - 10 of 31
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...cancer-promoting chemokines. TARGET/MARKER/PATHWAY: Kruppel-like factor 7 (KLF7); discs large MAGUK scaffold protein 3 (DLG3; SAP102); syntaxin...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...addition, senrebotase (AGN-214868), a Phase II compound that Ipsen gained in its 2013 acquisition of Syntaxin Ltd....
...even which cell types they target. Ipsen added the recombinant capabilities through a partnership with Syntaxin Ltd....
...AGN-214868 ; SXN100323), a targeted secretion inhibitor that has completed a Phase II trial, which Syntaxin...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...expression of the miR-183 complex could help treat pain. Karolinska Institute Translation in Brief Stroke Syntaxin...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Neurology

...the scrambled peptide. Next steps could include testing the compound in other stroke models. TARGET/MARKER/PATHWAY: Syntaxin...
...Neurodegenerative Diseases, Pittsburgh, Pa. email: redox@pitt.edu Julian Zhu University of Pittsburgh HIV tat protein (HIV tat) Potassium channel Kv2.1 (KCNB1) Syntaxin...
BioCentury | Mar 31, 2014
Finance

LSP's steady hand

...Inc. with a lead HCV vaccine program in Phase II development. Another recent exit was Syntaxin Ltd....
...in the company's £16 million ($32.8 million) series B round in 2007. At the time, Syntaxin's...
...a recombinant therapeutic protein that was in preclinical development to treat respiratory diseases. Last year, Syntaxin...
BioCentury | Feb 3, 2014
Company News

NightstaRx management update

...London, U.K. Business: Gene/Cell therapy, Ophthalmic Hired: Melanie Lee as CEO, formerly CEO of Syntaxin Ltd....
BioCentury | Jan 30, 2014
Financial News

NightstaRx debuts with L12 million from Syncona

...choroideremia, an inherited form of progressive blindness. NightstaRx's CEO is Melanie Lee, formerly CEO of Syntaxin Ltd....
BioCentury | Jul 22, 2013
Finance

Highlights of weekly biotech stock moves

...Euronext:IPN; Pink:IPSEY) edged down €0.11 to €30.01 last week after acquiring the 90% of partner Syntaxin Ltd....
...million) in cash up front, plus about €130 million ($169.8 million) in milestones. Ipsen gains Syntaxin's...
BioCentury | Jul 22, 2013
Company News

Ipsen, Syntaxin, Harvard deal

...Ipsen acquired the 90% of partner Syntaxin it did not already own for €28 million ($36.6...
...Bristows LLP advised Ipsen, and Rothschild and Allen & Overy LLP advised Syntaxin. Ipsen and Syntaxin...
...Ipsen and Syntaxin partnered in 2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's...
BioCentury | Jul 16, 2013
Company News

Ipsen acquires Syntaxin

...Ipsen Group (Euronext:IPN; Pink:IPSEY) acquired the 90% of partner Syntaxin Ltd. (Abingdon, U.K.) it did not already...
...in cash up front, plus about EUR 130 million ($169.8 million) in milestones. Ipsen gains Syntaxin's...
...Ipsen and Syntaxin partnered in 2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's...
Items per page:
1 - 10 of 31